Rheumatology

ASCO Journal Club

Journal Club Q&A done in partnership with ASCO the Journal of Clinical Oncology

Questions discussed in this category

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answer available

Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?

1 Answer available

Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Immunother Cancer, 2019 Aug 22

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events.

Journal for immunotherapy of cancer, 2017-11-21

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Cancer management and research, 2017

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Related Topics in Rheumatology